Torray Investment Partners LLC Has $17.45 Million Position in Royalty Pharma plc (NASDAQ:RPRX)

Torray Investment Partners LLC trimmed its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 20.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 684,007 shares of the biopharmaceutical company’s stock after selling 173,912 shares during the quarter. Royalty Pharma comprises about 2.5% of Torray Investment Partners LLC’s portfolio, making the stock its 9th biggest holding. Torray Investment Partners LLC owned approximately 0.12% of Royalty Pharma worth $17,449,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the stock. Keene & Associates Inc. lifted its position in shares of Royalty Pharma by 1.9% during the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock valued at $495,000 after acquiring an additional 370 shares during the period. Blue Trust Inc. lifted its position in shares of Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 376 shares during the period. Sanctuary Advisors LLC lifted its position in shares of Royalty Pharma by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock valued at $1,068,000 after acquiring an additional 388 shares during the period. Aurora Investment Counsel lifted its position in shares of Royalty Pharma by 1.0% during the 3rd quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock valued at $1,427,000 after acquiring an additional 512 shares during the period. Finally, GAMMA Investing LLC lifted its position in shares of Royalty Pharma by 31.4% during the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 590 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RPRX has been the subject of several recent analyst reports. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and an average target price of $41.60.

Royalty Pharma Price Performance

Shares of RPRX opened at $33.86 on Tuesday. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The business has a 50-day simple moving average of $30.23 and a two-hundred day simple moving average of $28.24. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a market cap of $19.52 billion, a PE ratio of 23.35, a PEG ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a $0.22 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date is Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.60%. Royalty Pharma’s dividend payout ratio is presently 60.69%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.